Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 13/20 | 0.68 |
| ▸ | CLK2 | P49760 | 4/20 | 0.62 |
| ▸ | CLK3 | P49761 | 4/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714876 | 1.00 | ITK (0.68) | ITKCLK2CLK3DYRK1ALRRK2 | |
| SCHEMBL18426816 | 0.87 | CLK2 (0.60) | ITKCLK2CLK3DYRK1ARIPK1 | |
| SCHEMBL18426535 | 0.86 | CLK2 (0.70) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18426993 | 0.84 | ITK (0.76) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18441663 | 0.83 | CLK2 (0.65) | ITKCLK2CLK3DYRK1ALRRK2 | |
| SCHEMBL29714858 | 0.83 | ITK (0.68) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL2274785 | 0.83 | ITK (0.68) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18441572 | 0.82 | DYRK1A (0.72) | CLK2CLK3DYRK1ARIPK1 | |
| SCHEMBL145584 | 0.82 | ITK (1.00) | ITK | |
| SCHEMBL29470244 | 0.82 | ITK (1.00) | ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197523-A1 | MOTORIZED INJECTION SYSTEM AND METHODS OF USE | MEIRAGTX UK II LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| CN-116600752-A | Motorized injection system and method of use | 梅里特斯英国第二有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-10350199-B2 | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-10350199-B2 | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180207141-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-26 | — | — | US | disclosed |
| US-20180207141-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-26 | — | — | US | disclosed |
| WO-2017024021-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024021-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350199-B2 | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | WNT1, WNT3, WNT3A | ITK 1594/4885CLK2 779/4885CLK3 759/4885 |
| US-20180207141-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | ITK 1594/4885CLK2 779/4885CLK3 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.